We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Friedreich ataxia
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Friedreich’s ataxia (FA) is an inherited genetic condition. FA affects the part of the brain that controls movement and balance (the cerebellum). It also affects the nerves which carry signals from the brain to the rest of the body. People with FA experience symptoms that get worse over time. These include movement and balance difficulties, speech and swallowing issues, and muscle weakness. Other symptoms can include diabetes mellitus and heart problems. Many people with FA live with significant physical disability and reduced life expectancy. Currently, there is no cure for FA, and more research on this rare condition is needed. Performing clinical trials in rare conditions like FA is challenging. Current clinical rating scales and many outcome measures are subjective. The results may differ depending on who performs the assessment. Often, assessments are not sensitive enough to detect changes over a short time frame. Instrumented assessments of gait and balance, may be useful as alternative outcome measures. They are already used to assess gait and balance issues (ataxia) in some conditions. They are less subjective than current measures and may be better at detecting changes. This study will investigate instrumented assessments of gait and balance in FA. This will be in a specialist gait laboratory and via wearable sensors. It will investigate if these assessments show a consistent pattern. It will also check if these assessments are sensitive enough to measure changes in FA over a year compared to current outcome measures.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
1. Lacking the capacity to provide informed consent2. Enrolled in interfering therapy or clinical drug trial currently or within last 3 months3. Pregnancy at the time of enrolment4. Any other reason, which in the opinion of the recruiting investigator would preclude involvement in the study
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Yi Shiau
Ng
+44 (0)191 208 3084
yi.ng@newcastle.ac.uk
The study is sponsored by Newcastle University and funded by l'Association Française de l'Ataxie de Friedreich (AFAF).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 57586
You can print or share the study information with your GP/healthcare provider or contact the research team directly.